血小板与淋巴细胞比值对肝细胞癌患者预后影响的Meta分析

张婷婷; 王湘漪; 郭紫薇; 丁小胜; 梁军

doi:10.3971/j.issn.1000-8578.2018.18.0151

血小板与淋巴细胞比值对肝细胞癌患者预后影响的Meta分析

Prognostic Significance of Platelet-lymphocyte Ratio in Hepatocellular Carcinoma Patients: A Meta-analysis

摘要

摘要:
目的评价血小板与淋巴细胞比值（Platelet-lymphocyte ratio, PLR）对肝细胞癌（Hepatocellular carcinoma, HCC）的预后价值。
方法以PubMed、Embase、Web of Science数据库中已发表的英文文献作为检索的主要来源，检索时限为数据库建立至2016年12月31日，按照拟定的纳入和排除标准，筛选符合系统评价标准的研究。采用Meta分析方法评PLR对HCC的预后意义。数据分析软件采用STATA 12.0。异质性检验采用Cochran's Q检验，根据检验结果选择模型进行相应的效应量合并，最终将合并分析所得出的HR/OR值及其95%CI作为效应分析的统计量。
结果来自6篇文献的1 215例HCC患者纳入研究。对于总体HCC人群而言，高水平PLR的HCC患者OS明显较短（HR=1.55, 95%CI: 1.06-2.29, P=0.025），但与DFS无相关性（P=0.222）。
结论 PLR是影响HCC患者远期预后的独立风险因素。检测治疗前PLR水平对判断肝细胞癌患者的临床预后具有一定的意义。

Abstract:
Objective To evaluate the prognostic value of platelet-lymphocyte ratio(PLR) in the patients with hepatocellular carcinoma(HCC).
Methods The original articles which were published in PubMed, Embase and Web of Science databases until Dec 31th, 2016 were the primary source of the current research. Studies which met with the proposed inclusion and exclusion criteria would be selected into the meta-analysis to evaluate the prognostic value of PLR in HCC. STATA 12.0 was used for data analysis and consolidation. Heterogeneity was tested and evaluated by Cochran's Q statistic method and the effective models were chosen in order to combine the corresponding effect measures. Meta-analysis was performed by HR/OR and their 95%CI as effect measure.
Results A total of 1215 patients from six studies were included to evaluate the association between PLR and clinical outcome of HCC patients. High PLR indicated poor OS significantly (HR=1.55, 95%CI: 1.06-2.29, P=0.025), but had no impact on DFS(P=0.222).
Conclusion PLR is an independently prognostic biomarker for the long-term outcome of HCC patients. Detection of PLR before treatment may contribute to predict the prognosis of HCC patients.

HTML全文

参考文献(26)

施引文献

资源附件(0)